Therapy Areas: Central Nervous System
Precision NeuroMed's glioblastoma multiforme treatment granted FDA Orphan Drug Designation
8 October 2025 - Precision NeuroMed (PNM), a clinical-stage biotechnology company developing advanced drug delivery technologies for central nervous system (CNS) diseases, announced on Tuesday that th...
MapLight Therapeutics commences IPO
7 October 2025 - MapLight Therapeutics Inc, a California-based clinical-stage biopharmaceutical company focused on treatment for debilitating central nervous system disorders, said on Monday that it h...
SineuGene Therapeutics' ALS drug Investigational New Drug application receives Chinese regulatory approval
18 August 2025 - SineuGene Therapeutics Co, Ltd, a China-based, clinical-stage biotechnology company that mainly focuses on gene therapies for neurological disorders, announced on Friday that China�...
South Rampart Pharma reports new study findings showing SRP-001 delivers central, non-toxic pain relief
29 July 2025 - South Rampart Pharma Inc, a US-based clinical-stage biopharmaceutical company focused on innovative non-opioid pain therapies, announced on Monday the publication of new research in the...
NFL Biosciences and McLean Hospital collaborate to advance NFL-101 mechanism research
28 July 2025 - Biopharmaceutical company NFL Biosciences (Euronext Growth Paris: ALFNL) announced on Monday that it has entered into a scientific collaboration with McLean Hospital, part of the Mass G...
Neuraxpharm launches Neuraxpharm Australia
22 July 2025 - Neuraxpharm Group, a Spain-based specialty pharmaceutical company focused on the treatment of central nervous system (CNS) disorders, announced on Monday the launch of a new affiliate, ...